Sector News

Does Bristol-Myers Squibb’s new activist investor want to stall its Celgene buyout?

February 5, 2019
Life sciences

Analysts and investors have both expressed concerns over Bristol-Myers Squibb’s $74 billion Celgene deal agreement. And an activist may be joining that list.

Known agitator Starboard Value has taken a stake in the New Jersey drugmaker, Bloomberg’s sources say, though the size of that stake and the hedge fund’s plans are still unclear. A BMS spokeswoman declined to comment.

Bristol-Myers and Celgene agreed to tango early in the year, signing a mammoth deal they said would make a combined company a leader in oncology and immunology. But analysts have pressed Bristol on lower-than-expected revenue growth guidance it rolled out late last month.

One course of action Starboard may be angling for? A sale, Bloomberg Intelligence Sam Fazeli told the news service. “But there are only a very few companies that can actually do that,” he said. AbbVie, Pfizer and Novartis top the list, “but all these would require a lot of synergies to be accretive.”

At one time, analysts predicted Bristol’s sagging shares could make it a takeover target for rivals interested in getting their hands on its immuno-oncology assets. As recently as BMS’ fourth-quarter earnings call last week, analysts asked executives whether they did the Celgene deal to avoid an unwanted buyout bid.

But these days, there doesn’t seem to be a lot of interest in megamergers on the part of some of the most likely parties. Pfizer, who many thought could go after Bristol, has said repeatedly that it plans to stick to smaller bolt-on acquisitions.

AbbVie CEO Richard Gonzalez recently told investors that a “big deal” is “not something that we are contemplating.” And Celgene, which surveyed the landscape before inking its pact with Bristol, didn’t find much interest in megabuys, either; it approached just one other potential buyer that squarely turned it down.

“There has been activist involvement in Bristol over the past couple years that may have contributed to some changes at the company, but we would be surprised if activists are successful in pushing for a larger change, such as trying to get Bristol to sell itself,” Credit Suisse analyst Vamil Divan wrote in a Monday note to clients, adding that he and his colleagues continue to expect deal to close as planned.

Meanwhile, Starboard has been active in the pharma world over the last few years, most recently convincing Perrigo to jettison its prescription drugs business. Before getting involved with the Dublin drugmaker, it pressured California’s Depomed to go up for sale.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).